Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry

A. Viudez,Alberto Carmona-Bayonas,Jesús Gallego,A. Lacalle,Raquel Hernández,Juana María Cano,Ismael Macias,Ana Custodio,E. Martinez de Castro,Ariadna Sánchez,L. Iglesia,P. Reguera,Laura Visa,A. Azkárate,M. Sánchez Cánovas,M. Mangas,M. L. Limon,A Martinez Torròn,Enrique Asensio,Avinash Ramchandani,A. Martín Carnicero,Alicia Navajas Hurtado,Paula Cerda,Marcelo Garrido,R. Sánchez-Bayonas,Rebeca Serrano,Paula Jiménez-Fonseca

Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry

2019

Background The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression.

Keywords:

Cancer
General surgery
Clinical trial
Medicine
Oncology
Internal medicine
Chemotherapy
Discontinuation
Adverse effect
Hazard ratio
Tumor progression
Regimen
ECOG Performance Status

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations